![]() |
|
|
Forward to a colleague |
||
Access Full Stories The US Food and Drug Administration (FDA) has given stakeholders an extra month to get their views in on scrapping epinephrine inhalers containing CFCs... Read Icahn invests in Genzyme, prompts takeover rumours The man often credited with causing Biogen Idec to be put up for sale, billionaire corporate raider Carl Icahn, has invested in Genzyme and promptly started industry tongues wagging about a takeover... Read AMRI continues growth Albany Molecular Research Inc (AMRI) recently turned in Q3 results, posting figures buoyed by continued demand for its pharmaceutical development services... Read Pfizer, Nektar agreement not so sweet after all? Pfizer yesterday announced a multi-million dollar pay-off to ex-partner Nektar Therapeutics, but the details of the deal reveal not only Nektar's concerns for its future, but also that Pfizer is still keeping its... Read AstraZeneca in 'serious trouble', say analysts An analyst report released yesterday identified AstraZeneca as being in 'serious trouble' and branded it as potentially the 'worst [large cap] performer in [the] entire sector' over the next eight years... Read |
||||||||||||||
All News Headlines for: November | October | September |
||||||||||||||
![]() Advanced Chiral Chromatography DAICEL announce the launch of CHIRALPAK® IC. The combination of CHIRALPAK® IA, IB and now IC provides a screening set of column with exceptionally high success rates. The chiral separation of > 99% of all small molecules is attained using just 3 columns and four... Click Here | ||||||||||||||
|
Related Industry News Stem cell breakthrough avoids the embryo controversy US researchers have developed a way of creating primate embryonic stem cells that avoids the need to use fertilised embryos, potentially leading to more ethical ways of curing degenerative diseases... Read Preclinical services news in brief In this week's review of activity within the preclinical research services arena, news has emerged involving GATC Biotech, NextGen Sciences and Genedata... Read Targeted lupus treatment on the horizon Researchers have uncovered some of the underlying causes of lupus, and have even suggested certain targeted therapies to tackle the autoimmune disease... Read Evotec's metamorphosis erodes profit Evotec's bid to distance itself from being a services business and eventually morph into a fully fledged pharma company has been felt on the company's balance sheet during the third quarter... Read
|
||||||||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@In-PharmaTechnologist.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||